40c3ad50-2b9b-4833-ab2f-c8328075da55 - samples
Ontology highlight
ABSTRACT:
PROVIDER: EGAD00001006887 | EGA |
REPOSITORIES: EGA
Similar Datasets
Project description:Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples).
Here we are submitting two datasets that contain NGS files from gastrointestinal rare cancers (n=119):
- Dataset 2 (87 patients): Intra-hepatic cholangiocarcinoma (n=47), Extra-hepatic, cholangiocarcinoma (n=16), Not specified Cholangiocarcinoma (n=9), Small bowel adenocarcinoma (n=6) and other rare GI cancer (n=9)
| EGAD00001008968 | EGA
Project description:Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples).
Here we are submitting two datasets that contain NGS files from gastrointestinal rare cancers (n=119):
- Dataset 1 (32 patients): Mesothelioma of the peritoneum (n=21) and Pseudomyxoma peritonei/mucinous adenocarcinoma of the appendix (n=11)
- Dataset 2 (87 patients): Intra-hepatic cholangiocarcinoma (n=47), Extra-hepatic, cholangiocarcinoma (n=16), Not specified Cholangiocarcinoma (n=9), Small bowel adenocarcinoma (n=6) and other rare GI cancer (n=9)
| EGAS00001006299 | EGA
Project description:This dataset contains somatic alteration calls summarized at the gene level for 715 patients profiled by FoundationOne (Foundation Medicine).
| EGAD00001006616 | EGA
Project description:RNA-seq analysis of the transcriptome of wild type C.jejuni NCTC11168, and of an rpoN mutant of the same strain, both grown in vitro. ArrayExpress Release Date: 2011-06-14 Publication Title: Quantitative RNA-seq analysis of the transcriptome of Campylobacter jejuni Publication Author List: Roy R. Chaudhuri, Lu Yu, Alpa Kanji, Timothy T. Perkins, Paul P. Gardner, Jyoti Choudhary, Duncan J. Maskell, Andrew J. Grant Person Roles: submitter Person Last Name: Chaudhuri Person First Name: Roy Person Mid Initials: R Person Email: roy.chaudhuri@gmail.com Person Phone: 441000000000 Person Address: Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, United Kingdom Person Affiliation: University of Cambridge
2011-07-14 | GSE30621 | GEO
Project description:Ovarian cancer is a global problem, is typically diagnosed at a late stage and has no effective screening strategy. Platinum-based chemotherapy or Poly(ADP-ribose) polymerase inhibitors (PARPis) treatment are most frequently applied for ovarian cancer patients who are inoperable and in the advanced stage. The recognition of homologous recombination deficiency (HRD) as a biomarker to predict the effect of Platinum-based or PARPis treatment. WGS and WES can detect tumor HRD status but have several disadvantages which restrict their clinical application. My choice HRD CDx and Foundation Focus CDx are approved by FDA for HRD detection, however, whether they are applicable to the Chinese population or not is unknown. In this study, we created an SNP-based Tg-NGS panel to fill in gaps in Chinese patients’ HRD screening. Our results showed that the panel is cost and time-saving compared with WGS, but equivalent with SNP microarray on CNV and HRD detection. In summary, this newly developed kit is promising in clinical application to guide ovarian cancer and even other cancer types therapy.
2023-02-21 | GSE203509 | GEO
Project description:<p>The Foundation Medicine adult cancer clinical dataset consists of 18,004 unique solid tumor samples that underwent genomic profiling on a single uniform platform as part of standard clinical care. The dataset is derived from the FoundationOne® genomic profiling assay version 2 that interrogates exonic regions of 287 cancer-related genes and selected introns from 19 genes known to undergo rearrangements in human cancer. Genomic DNA samples were sequenced to over 500x median coverage, and custom computational analyses identified all classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements). Since matched normal tissue was unavailable for analysis, these data underwent additional filtering to enrich for cancer-related events. The reported data includes genomic alterations that are known and suspected tumor drivers, as well as variants of unknown significance. To preserve patient anonymity, all known or suspected germline variants were removed from the data unless known to be associated with cancer development.</p> <p>The dataset contains genomic alteration profiles generated by FoundationOne version 2 testing for adult cancer patients (over 18 y.o.), and represents a vast diversity of tumor subtypes, including many rare diseases not profiled as part of large-scale profiling efforts. Cases are grouped into 16 broad disease categories containing tumors from 162 unique disease subtypes. Since specimens were profiled as part of clinical care, limited clinical parameters were available, including age, gender, tissue of origin, % of tumor nuclei, and diagnosis. Publication of this dataset is intended to allow the broad scientific community access to this unique cohort for use in scientific research projects of common and rare types of cancer, both for generating leads regarding causal mechanisms as well as cross-testing and confirming existing hypotheses. </p> <p>A pediatric cancer clinical dataset consisting of data from 1,215 patients under 18 y.o. is available separately at: <a href="https://pediatric-data.foundationmedicine.com.">FOUNDATION MEDICINE</a> </p>
| phs001179 | dbGaP
Project description:FoundationOne Data Release 1.0
| PRJNA335890 | ENA
Project description:Our study provided a comprehensive mechanistic understanding of the neurotoxic effects induced by MA at multi-omics resolution, and offered valuable insights for enhancing the rational application of traditional Chinese medicine containing aconitum in clinical practice.
2024-07-03 | GSE261320 | GEO